Fibrate therapy in patients with metabolic syndrome and diabetes mellitus

Current Atherosclerosis Reports

Volumn 8, Issue 5, 2006, Pages 356-364

  Dayspring, Thomas ^a   Pokrywka, Gregory ^b  

^a North Jersey Institute of Menopausal Lipidology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CLOFIBRATE; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SIMVASTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ENZYME DEFECT; GALLSTONE FORMATION; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; MYOSITIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PANCREATITIS; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOLIPIDEMIC AGENTS; METABOLIC SYNDROME X; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33748433528     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0032-x     Document Type: Review

References (70)

1. Szapary PO, Rader DJ: The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J 2004;148:211-21.
2. Björkegren J: Dual roles of apolipoprotein CI in the formation of atherogenic remnants. Curr Atheroscler Rep 2006, 8:1-2.
3. Brewer HB Jr: Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999, 83:3F-12F.
4. Pruneta-Deloche V, Ponsin G, Groisne L, et al.: Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients. Atherosclerosis 2005, 181:403-405.
5. Maria Maggi F, Raselli S, Grigore L, et al.: Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab 2004, 89:2946-2950.
6. Garvey WT, Kwon S, Zheng D, et al.: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
7. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
8. Kahn R, Buse J, Ferrannini E, et al.: The metabolic syndrome: time for a critical appraisal: joint statement from the Am Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
9. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
10. The FIELD Study Investigators: Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study); randomized controlled trial. Lancet 2005, 366:1849-1861.
11. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Eng J Med 1987, 317:1237-1245.
12. The DAIS Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
13. Tenenbaum A, Motro M, Fisman EZ, et al.: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2000, 102:21-27.
14. Rubins HB, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med 1999, 341:410-418.
15. Grundy SM, Cleeman JI, Bairey Merz CN, et al., for the Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:227-239.
16. American Diabetes Association: Standards of medical care in diabetes: 2006. Diabetes Care 2006, 29(Suppl) S18-S19.
17. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease. Risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37-45.
18. Koskinen P, Manttari M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
19. Ansquer JC, Foucher C, Rattier S, et al.: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005, 45:485-493.
20. Rubins HB, Robins SJ, Collins D, et al., for the VA-HIT Study Group: Diabetes, plasma insulin, and cardiovascular disease subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
21. Robins SJ, Rubins HB, Faas FH, et al., on behalf of the VA-HIT Study Group: Insulin resistance and cardiovascular events with low hdl cholesterol the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003, 26:1513-1517.
22. Otvos J, Collins D, Freedman DS, et al.: Low-density lipoprotein and high-density lipoprotein particle predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial Circulation 2006, In press.
23. Tenenbaum A, Motro M, Fisman EZ, et al.: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
24. Goldenberg I, Goldbourt U, Boyko V, et al.: Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol 2006, 97:466-471.
25. Arcavi L, Behar S, Caspi A, et al.: High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am Heart J 2004, 147:239-245.
26. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
27. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available at http://www.accordtrial.org/public/index.cfm. Accessed March 5, 2006.
28. Grundy SM, Vega GL, Yuan Z, et al.: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005, 95:462-468.
29. Winkler K, Weltzien P: Qualitative effect of fenofibrate and quantitative effect of atorvastatin in combined dyslipidemia with small dense LDL. Exp Clin Endocrinol Diabetes 2004, 112:241-247.
30. Koh KK, Quon MJ, Han SH, et al.: Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
31. Farnier M, Freeman MW, Macdonell G, et al., for the Ezetimibe Study Group: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005, 26:897-905.
32. Spencer GA, Wirebaugh S, Whitney EJ: Effect of a combination of gemfibrozil and niacin on lipid levels J Clin Pharmacol 1996, 36:696-700.
33. Whitney EJ, Krasuski RA, Personius BE, et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
34. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
35. Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR-a in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116:571-580.
36. Ramaswamy G, Karim MA, Gopal Murti K, Jackowski S: PPARa controls the intracellular coenzyme A concentration via regulation of PANK1a gene expression. J Lipid Res 2004, 45:17-31.
37. Li Y, Nara TY, Nakamura MT: Peroxisome proliferator-activated receptor alpha is required for feedback regulation of highly unsaturated fatty acid synthesis. J Lipid Res 2005;46:2432-2440.
38. Zhu D, Ganji SH, Kamanna VS, Kashyap ML: Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis 2002, 164:221-228.
39. Guerin M, Bruckert E, Dolphin PJ, et al.: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996, 16:763-772.
40. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression J Lipid Res 1996, 37:907-925.
41. Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem 1999, 9:139-149.
42. Schultze AE, Alborn WE, Newton RK, et al.: Administration of a PPAR-a agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J. Lipid Res 2005, 46:1591-1595.
43. Cavallero E, Dachet C, Assadolahi F, et al.: Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. Atherosclerosis 2003, 166:151-161.
44. Capell WH, DeSouza CA, Poirier B, et al.: Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003, 23:307-313.
45. Arakawa R, Tamehiro N, Nishimaki-Mogami T, et al.: Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005, 25:1193-1197.
46. Chapman JM: Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1-13.
47. Roglans N, Vazquez-Carrera M, Alegret M: Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol 2004, 59:855-861.
48. Ganotakis E, Tsimihodimos V, Bairaktari E, et al.: Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 2002, 165:187-188.
49. Chinetti-Gbaguidi G, Rigamonti E, Helin L, et al.: Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J Lipid Res 2005, 46:2717-2725.
50. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-a and PPAR-a activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
51. Li AC, Palinsk W: Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol 2006, 46:1-39.
52. Nigon F, Lesnik P, Rouis M, et al.: Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991, 32:1741-1753.
53. Despres JP, Lemieux I, Robins SJ: Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 2004, 64:2177-2198.
54. Tenenbaum A, Motrol M, Fisman EZ, et al.: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038.
55. Koh KK, Han FS, Quon MJ, et al.: Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
56. Wysocki J, Belowski D, Kalina M, et al.: Effect of micronized fenofibrate on insulin resistance in patients with metabolic syndrome, Int J Clin Pharmacol 2004, 42:212-217.
57. Li AC, Glass CK: PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004;45:2161-73.
58. Koh KK, Ahn JY, Han SH, et al.: Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis Atherosclerosis 2004, 174:379-383.
59. Chinetti-Gbaguida G, Fruchart JC, Staeils B: Pleiotropic effects of fibrates. Curr Atheroscler Rep 2005, 7:396-401.
60. Calabresi L, Gomaraschi M, Villa B, et al.: Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2002, 22:656-661.
61. Hottelart C, Esper NE, Rose E, Achard JM: Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002, 92:536-541.
62. Broeders N, Knoop C, Antoine M, et al.: Fibrate-induced increase in BUN and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000, 15:1993-1999.
63. Syvanne M, Whittall RA, Turpeinen U, et al.: Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 2004, 172:267-272.
64. Genest J, Frohlich J, Steiner G: Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in Type 2 diabetes mellitus. Am J Cardiol 2004, 93:848-853.
65. Dierkes J, Westphal S, Kunstmann S, et al.: Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 2001, 158:161-164.
66. Stulc T, Melenovsky V, Grauova B, et al.: Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition 2001, 17:721-723.
67. Prueksaritanont T, Zhao JJ, Ma B, et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Therapeutics 2002, 301:1042-1051.
68. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-122.
69. Corsini A, Bellosta S, Davidson MH: Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005, 96(Suppl):44K-49K.
70. Grundy SM: The changing face of cardiovascular risk. J Am Coll Cardiol 2005, 46:173-175.